Effect of photodynamic therapy with toloeidene blue photosensitizer on nonsurgical management of peri-implant mucosal inflammation and Its matrix metalloproteinase 8 and Cytokine Profile

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092411770N2

Enrollment

Registered

2017-01-12

Start date

2016-10-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implantitis. Gingivitis and periodontal diseases

Interventions

Intervention 1: control group: scaling and root planning alone. Intervention 2: intervention group: scaling & root planning and photodynamictherapy.

Treatment - Other

control group: scaling and root planning alone

intervention group: scaling & root planning and photodynamictherapy

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age greater than 18 years old; patients with peri-implant mucositis (probing depth =4 mm, BOP, no soft tissue recession with or without minimum bone resorption( = 2 mm) in periapical radiography); implant in function for 1=. Exclusion criteria: uncontrolled systemic disease; smoking; active periodontal disease; pregnancy or breastfeeding; radiotherapy of neck & head; drug and alcohol abuse; ingestion of systemic antibiotics within the last 3 months; persons with a history of continuous use drugs that alter the hard and soft tissue conditions( phenytoin,cyclosporine, calcium channel blockers, bisphosphonates, NSAIDs,...); pocket depth greater than 6 mm; receiving any treatment for peri-implant mucosal inflammation (PIMI) within last 3 months; indication for prophylactic systemic antibiotics; infectious diseases such as AIDS, hepatitis and tuberculosis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding on probing. Timepoint: base line, 2 weeks, 3 months. Method of measurement: probing.;Probing depth. Timepoint: base line, 2 weeks, 3 months. Method of measurement: probing.	—

Secondary

Measure	Time frame
Matrix metalloproteinase 8 in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA tests.;Interleukin-1ß level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.;Interleukin-6 level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.;TNF-alpha level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.	—

Measure

Time frame

Matrix metalloproteinase 8 in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA tests.;Interleukin-1ß level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.;Interleukin-6 level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.;TNF-alpha level in peri implant crevicular fluid. Timepoint: base line,2 weeks, 3 months. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Saadat

department of periodontics, Faculty of Dentistry

maryamdent87@gmail.com+98 41 3335 5969

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026